Pfizer Opens Cambridge R&D Center To Foster Collaboration
This article was originally published in The Pink Sheet Daily
The big pharma plays up its ability to work with external partners weeks after its attempted acquisition of AstraZeneca fell through. The new facility is part of its plan to increase ties between scientists.
You may also be interested in...
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.